https://www.taxtmi.com/caselaws?id=458780 Section 3(i) of the Patents Act, 1970 was interpreted to exclude diagnostic processes even where the claimed method is performed in vitro rather than on the human body. Reading the claims with the complete specification, the Madras High Court noted that the nucleic-acid analysis method was inherently capable of identifying sequence imbalance and enabling diagnosis of fetal chromosomal aneuploidy, so it fell within the diagnostic exclusion. The court further stated that the exclusion is not confined to definitive diagnosis or to in vivo methods, and that the patent application was therefore rightly refused. en-us Thu, 12 Oct 2023 00:00:00 +0530 Fri, 15 Nov 2024 13:20:14 +0530 TaxTMI RSS Generator https://www.taxtmi.com/caselaws?id=458780 Section 3(i) of the Patents Act, 1970 was interpreted to exclude diagnostic processes even where the claimed method is performed in vitro rather than on the human body. Reading the claims with the complete specification, the Madras High Court noted that the nucleic-acid analysis method was inherently capable of identifying sequence imbalance and enabling diagnosis of fetal chromosomal aneuploidy, so it fell within the diagnostic exclusion. The court further stated that the exclusion is not confined to definitive diagnosis or to in vivo methods, and that the patent application was therefore rightly refused. Case-Laws Indian Laws Thu, 12 Oct 2023 00:00:00 +0530 https://www.taxtmi.com/caselaws?id=458780